Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
(KSP-1007 + meropenem) by Sumitomo Pharma for Hospital Acquired Pneumonia (HAP): Likelihood of Approval
(KSP-1007 + meropenem) is under clinical development by Sumitomo Pharma and currently in Phase I for Hospital Acquired Pneumonia (HAP)....
(KSP-1007 + meropenem) by Sumitomo Pharma for Ventilator Associated Pneumonia (VAP): Likelihood of Approval
(KSP-1007 + meropenem) is under clinical development by Sumitomo Pharma and currently in Phase I for Ventilator Associated Pneumonia (VAP)....
KSP-1007 by Sumitomo Pharma for Ventilator Associated Pneumonia (VAP): Likelihood of Approval
KSP-1007 is under clinical development by Sumitomo Pharma and currently in Phase I for Ventilator Associated Pneumonia (VAP). According to...
DSP-0390 by Sumitomo Pharma for Oligodendroglioma: Likelihood of Approval
DSP-0390 is under clinical development by Sumitomo Pharma and currently in Phase II for Oligodendroglioma. According to GlobalData, Phase II...
DSP-0390 by Sumitomo Pharma for Anaplastic Astrocytoma: Likelihood of Approval
DSP-0390 is under clinical development by Sumitomo Pharma and currently in Phase II for Anaplastic Astrocytoma. According to GlobalData, Phase...
SMP-3124 by Sumitomo Pharma for Fallopian Tube Cancer: Likelihood of Approval
SMP-3124 is under clinical development by Sumitomo Pharma and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
SMP-3124 by Sumitomo Pharma for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
SMP-3124 is under clinical development by Sumitomo Pharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
SMP-3124 by Sumitomo Pharma for Uterine Cancer: Likelihood of Approval
SMP-3124 is under clinical development by Sumitomo Pharma and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...
SMP-3124 by Sumitomo Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
SMP-3124 is under clinical development by Sumitomo Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According to...
(KSP-1007 + meropenem) by Sumitomo Pharma for Complicated Intra-Abdominal Infections: Likelihood of Approval
(KSP-1007 + meropenem) is under clinical development by Sumitomo Pharma and currently in Phase I for Complicated Intra-Abdominal Infections. According...
DSP-1083 by Sumitomo Pharma for Parkinson's Disease: Likelihood of Approval
DSP-1083 is under clinical development by Sumitomo Pharma and currently in Phase II for Parkinson's Disease. According to GlobalData, Phase...